DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma

Information source: Fondazione Michelangelo
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hodgkin Lymphoma

Intervention: Bleomycin (Drug); Etoposide (Drug); Doxorubicin (Drug); Cyclophosphamide (Drug); Vincristine (Drug); Procarbazine (Drug); Prednisone (Drug); Doxorubicin (Drug); Bleomycin (Drug); Vinblastine (Drug); Dacarbazine (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Fondazione Michelangelo

Official(s) and/or principal investigator(s):
Alessandro M Gianni, MD, Study Chair, Affiliation: Fondazione IRCCS Istituto Nazionale Tumori di Milano


The choice of a preferred first-line treatment requires balancing the desire for optimal disease control with the occurrence of early and late treatment-related effects. To fully assess this balance, the treatment decision process should ideally take into account the outcome following a consistent second-line therapy, in particular when tolerated, widely applicable and highly effective salvage regimens exist, like in Hodgkin lymphoma failing initial chemotherapy.

Clinical Details

Official title: Prospective Randomized Comparison of ABVD Versus BEACOPP Chemotherapy With or Without Radiotherapy for Advanced Stage or Unfavorable Hodgkin's Lymphoma (HL)

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Freedom from first progression at 5 years

Secondary outcome:

Freedom from second progression at 5 years

Overall survival at 5 years

Number of participants with acute adverse events at initial therapy and at salvage therapy as a measure of safety and tolerability

Number of participants long term sequelae

Detailed description: During the last two decades ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) has been considered as the standard of care for advanced HL, however 20-30% of the patients fail to achieve a durable complete remission and need a salvage treatment. After a state-of-the art-salvage program including high-dose chemotherapy and autologous hematopoietic stem cell support (ASCT) at least half of these patients achieve a durable disease control. Recently the German Hodgkin Study Group (GHSG) has developed a new regimen, BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone), administered with or without dose escalation. In an interim analysis after 23 months follow-up, BEACOPP demonstrated a higher activity compared to COPP/ABVD with a superior freedom from treatment failure (84% versus 75%, P=.034). Despite the improved efficacy a substantial proportion of patients receiving escalated BEACOPP experienced severe acute hematologic toxicity (grade 3-4 leucopoenia, thrombocytopenia and anemia occurred in 78% , 36% and 27% of the cycles administered, respectively) and 1. 8% fatal acute toxicities were reported. Moreover of greater concern is the incidence of almost fatal secondary acute leukemia and myelodysplastic syndrome (3 cases in 323 patients). The choice of first-line treatment requires balancing the desire for optimal disease control with the occurrence of early and late treatment-related toxicities. Long-term outcome following an optimal salvage treatment, consisting in high-dose chemotherapy with ASCT should also be taken into consideration. In the present study we plan to compare the efficacy and toxicity of two therapeutic strategies consisting in two different first-line treatments followed by a pre-planned salvage program, when indicated


Minimum age: 17 Years. Maximum age: 60 Years. Gender(s): Both.


Inclusion Criteria:

- Histologically confirmed, newly diagnosed Hodgkin's lymphoma (pathological review

diagnosis available)

- No prior treatment

- Stage II B, III A and B, IV A and B

- Normal hematopoietic function as measured by leucocytes equal to or greater than

3500/mm3, neutrophils equal to or greater than 1500/mm3, platelets equal to or greater than 100000/mm3

- Normal renal function (serum creatinine < 1,5x ULN) and normal liver function

(SGOT/SGPT equal to or lower than 2. 5x ULN; bilirubin equal to or lower than 1. 5x ULN)

- No significant history or current evidence of cardiovascular disease, or major

respiratory disease

- No severe neurologic or psychiatric disease

- No other malignancy except basal cell carcinoma of the skin and/or in situ cervical

carcinoma of the uterus

- Serological negativity for hepatitis B or C or HIV infection

- ECOG performance status equal to or lower than 2

- Life expectancy of at least three months

- Effective contraception in all patients and a negative pregnancy test for women of

childbearing potential

- Written informed consent and consent to a regular follow-up in the outpatient clinic

Exclusion criteria:

- Sever central nervous system or psychiatric disease

- History or current evidence of clinically significant cardiac disease (congestive

heart failure, uncontrolled hypertension, unstable coronary artery disease or myocardial infarction or severe arrhythmias. Left ventricular ejection fraction < 50% at rest by echocardiography or < 55% by isotopic measurement

- Serological positivity for HBV, HCV or HIV

- History or current evidence of malignancy other than basal cell carcinoma of the

skin, carcinoma in situ of the cervix

- Lactating or pregnant women

Locations and Contacts

Fondazione IRCCS Istituto Nazionale di Tumori di Milano, Milano, Italy
Additional Information

Starting date: March 2000
Last updated: August 11, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017